6 ï <1

(Se 2552)

30, 2020

D 0301,

52

A 24 , DA 0302. 2 (2D•)

C

C 0110,

2D

C 0111, D -4

C 0112, -2

D 24 2020 A

D A 80

C B949.6 30, 2020.

C 30, 2020
B180.5 B112.3


B54.3
32.6% B112.3
30, 2020, 30, 2019.

B62.0 26.3%
B173.5 30, 2020,
30, 2019.

B61.8 26.3% B173.7
30, 2020, 30, 2019.

Trial #	Drugs	Disease indication	Study type	Pre-clinical	Phase I	Phase II	Phase III	NDA
HMM0301	Dorzagliatin	Drug naïve T2D	Registration trial					
HMM0302	Dorzagliatin & metformin	Metformin tolerated T2D	Registration trial					
HMM0311	Dorzagliatin +/vs OAD	Metformin tolerated T2D	Label expansion					
HMM0312	Dorzagliatin +/vs OAD	Metformin tolerated T2D	Label expansion					
HMM0109	Dorzagliatin	Hepatic impaired T2D	Label expansion					
HMM0110	Dorzagliatin	Renal impaired T2D	Label expansion					
HMM0111	Dorzagliatin + DPP-4							

C[illegible]A1[illegible]52[illegible]



(N=150)
8.35
(N=307)
7.20
(N=245)
7.18
(N=284)
6.95
(N=105)
HbA1c level by visit (%)
8.00
7.50
7.00
6.50
6.00
0
4w
8w
12w
16w
20w
24w
Double-Blind Treatment
Open-label Treatment
Dorzagliatin
Placebo

Figure


A [illegible] 2D [illegible] H444_0110, H444_0111, H444_0112 [illegible] H444_0301 [illegible]


1, 2020, DA 0302. DA 0302

2D









[illegible]

[illegible] 30, 2020 [illegible] B0.1 [illegible] B2.2 [illegible] 30, 2019, [illegible] 2019.

[illegible]

[illegible]

	[illegible]30,			
	2020	%	2019	%
	[illegible] '000		[illegible] '000	
D [illegible] C	46,565	41 %	85,342	51 %
D [illegible]	225	0 %	308	0 %
C [illegible] C	4,652	4 %	17,966	11 %
C	55,261	50 %	54,297	33 %
D [illegible]	1,272	1 %	2,018	1 %
	4,278	4 %	6,572	4 %
	112,253	100.0 %	166,503	100.0 %

[illegible] B54.3 [illegible] B112.3 [illegible] 30, 2020 [illegible] B166.5 [illegible] 30, 2019.

[illegible]

[illegible] B38.8 [illegible] [illegible] 52-[illegible]

D[illegible]0301 [illegible] 2020 [illegible]

DA [illegible]0302 [illegible] D [illegible] 2018;

[illegible] B13.3 [illegible]

Notes

[illegible] B167.4 [illegible] 30, 2020. A [illegible] 30, 2020, [illegible] B949.6 [illegible].

A [illegible] 30, 2020, [illegible] C [illegible].

6 [illegible]

[illegible]:

	[illegible]30,	
	2020	2019
	’000	’000
&D [illegible]	91,247	145,572
A [illegible]		
[illegible]	27,386	20,126
[illegible]	48,772	32,456
	76,158	52,582
	167,405	198,154

6 [illegible]

[illegible] 30, 2019 [illegible] 2020:

	[illegible]30,	
	2020	2019
	’000	’000
[illegible]	(167,405)	(198,154)
[illegible] ([illegible])	2,871	(1,666)
[illegible] ([illegible])	(3,832)	409
[illegible]	12,350	2,490
[illegible]	(156,016)	(196,921)

[illegible]

[illegible]

D[illegible] 30, 2020, [illegible] B167.4 [illegible] B173.5 [illegible] B29.2 [illegible] B23.1 [illegible] 30, 2020 [illegible]

D[illegible] 30, 2019, [illegible] B198.2 [illegible] B235.5 [illegible] B40.0 [illegible] B2.7 [illegible] 30, 2019 [illegible]

[illegible]

[illegible] B2.9 [illegible] 30, 2020, [illegible] B1.7 [illegible] 30, 2019, [illegible]

[illegible]

[illegible] B3.8 [illegible] 30, 2020, [illegible] B0.4 [illegible] 30, 2019, [illegible]

[illegible]

[illegible] B1,011.70 [illegible] D[illegible] 31, 2019 [illegible] B868.5 [illegible] 30, 2020. C[illegible] [illegible] B1,120.5 [illegible] D[illegible] 31, 2019 [illegible] B961.6 [illegible] 30, 2020, [illegible] B1,105.6 [illegible] D[illegible] 31, 2019 [illegible] B949.6 [illegible] 30, 2020, [illegible] 30, 2020.

[illegible]

[illegible] A [illegible] C [illegible]

A [illegible] B ([illegible] A B). [illegible] A [illegible] 16 [illegible] C [illegible] -19- [illegible] C [illegible].

[illegible]

A [illegible] 30, 2020, [illegible] B87.5 [illegible] :

	[illegible] 30, 2020 ₦'000	[illegible] 31, 2019 ₦'000
C[illegible]	14,822	12,019
[illegible]	72,652	77,959
	87,474	89,978

[illegible] 30, 2020 [illegible]. A [illegible] 30, 2020, [illegible].

[illegible]

[illegible]


[illegible] C [illegible]

A [illegible] B C,


C [illegible]


[illegible]

C [illegible],



	As at 30, 2020	As at 31, 2019
	'000	'000
	$ (29,140)	(42,433)
	$ (2,330)	(2,634)





		2020	2019
		’000	’000
	3	3,554	3,379
		3,463	1,995
A		(65,972)	(74,242)
		(2,247)	(129)
		(112,253)	(166,503)
	4	(173,455)	(235,500)
	5		
		(173,455)	(235,500)
		(202)	
		(173,657)	(235,500)
		(173,657)	(235,500)
		(173,657)	(235,500)

30, 2020

1.

C C
10, 2009 14, 2018.
B 309, C 1-1104, C
C 275 A, D, 201203, C.

C
5552, 2D.

2.

A 34 (A 34) A
B A 16
( )

C B,

3.

	30, 2020	
	2020 ' 000	2019 ' 000
B ( )	3,167	3,337
	327	42
	60	
	3,554	3,379

:

4. [illegible]

[illegible]:

	[illegible]30, 2020 '000	2019 '000
D[illegible]	2,277	1,504
D[illegible]	10,106	2,135
A[illegible]	137	85
[illegible]):		
[illegible]	60,624	56,124
[illegible]	1,657	2,687
[illegible]	30,216	42,046
	92,497	100,857
A[illegible]	680	680
[illegible]	785	1,620

[illegible]:

C -19. A A (2020) .11, C D-19 2020.

5. [illegible]

C C C

C (•) C 25 % C C

D[illegible]

6. [illegible]

D 2011, C (A A •) A (•) C (•). A A C $2.0 2012.

2017, C $1.0 C ( )

C $4.0
C ( ) $33.0
C ( ).
C $15.0
$500.0 $40.0
$1.0
C

7.

C
:

:

	30,	
	2020	2019
	' 000	' 000
	(	(
C	(173,455)	(235,500)

:

	30,	
	2020	2019
	(	(
	948,878,897	939,507,659

30, 2020 2019
C .

30, 2020 2019

8.

D 30, 2020, B1,498,000 ( ) (30, 2019: B4,359,000 ( )) 30, 2020 B10,209,000 ( ) (D 31, 2019: B10,988,000 ( )).

9.

	As at 30, 2020	As at 31, 2019
	HK$'000	HK$'000
	1,986	2,838
	1,832	1,462
	3,504	4,117
	31,270	26,248
	8,159	10,552
	339	342
	47,090	45,559
	11,977	14,852
	35,113	30,707
	47,090	45,559

10.

0.001 % 1.2 % 30, 2020 (D 31, 2019: 0.05 % 2.80 %).

11.

	As at 30, 2020	As at 31, 2019
	HK$'000	HK$'000
	46,685	47,941
	16,004	28,577
	4,132	3,660
	1,857	6,662
	1,065	1,477
	69,743	88,317

30

		As at December 30, 2020 RM'000 (Audited)	As at December 31, 2019 RM'000 (Audited)
	30	46,685	47,491
		46,685	47,491

12.

C

13.

30, 2020

C C C A 14
C C
C D .

B C
C C 30, 2020. B
B .

A C
D . C 25, 2020.

A D
C 大唐西市絲路投資控股有限公司 (C : 620)
29 2020.

D 13.51B .

30, 2020 , D
2410
A • (2410•) .
C A .

C
C 30, 2020,
.

2020
( ) C ( ). C
30, 2020
C
C .

2019 C A 22, 2020.

C :

Type	Date	Tranche	Number of Shares Underlying Options	Weighted Average Exercise Price
Grant: Director				
D C	Exercisable on			
	A : 25, 2019	1	12,079,000	$8.89
C	Exercisable on			
C	A : 17, 2019	1	300,000	$8.89
Grant: Employee				
	Exercisable on			
	A : 29, 2018	2	75,000	$6.81
	A 26, 2018	3	500,000	$8.17
	A : D 31, 2018	4	500,000	$8.06
	A : 15, 2019	1	8,540,300	$8.89
	A : 19, 2019	5	500,000	$6.80
Grant: Consultant				
	Exercisable on			
	A : 15, 2019	1	200,000	$8.89

(1) 8, 2019 23, 2019 11, 2019 75 % 36 $8.866.

(2) 29, 2018 29, 2018 75 % 36 $7.192.

(3) 26, 2018 26, 2018 75 % 36 $7.970.

(4) D. 31, 2018 D. 31, 2018 75 % 36 $8.30.

(5) A 29,2019 19, 2019 75 % 36 $6.80.



( )• ( ) C $0.001

$• A

A

B B

C

D

, A 17, 2020

A C D C C C C D C C A C